How Aging Macrophages Drive Plaque Buildup and New Ways to Stop Them
Senescent macrophages and cell death pathways fuel atherosclerosis — and new drug targets may finally interrupt the cycle.
Summary
Atherosclerosis, the leading cause of death worldwide, is driven in large part by dysfunctional immune cells called macrophages. As macrophages age inside arterial plaques, they enter a state called senescence — becoming permanently growth-arrested and releasing inflammatory signals that destabilize plaques and impair the cleanup of dead cells. They also undergo various forms of programmed cell death, including pyroptosis and necroptosis, which enlarge the dangerous necrotic cores inside plaques. This review maps the shared molecular pathways governing both processes — including NF-κB, mTOR, and p53 — and highlights emerging therapies such as senolytics, NLRP3 inhibitors, and ferroptosis suppressors. Natural compounds like quercetin and melatonin are also examined for their ability to disrupt these harmful processes, pointing toward dual-targeted strategies for reducing cardiovascular disease risk.
Detailed Summary
Atherosclerosis remains the world's top killer, and understanding exactly why arterial plaques form, grow unstable, and rupture is essential to combating it. A growing body of evidence implicates macrophages — the immune cells that patrol arterial walls — as central culprits. When macrophages accumulate oxidized lipids and experience chronic stress, two interrelated processes take hold: cellular senescence and programmed cell death (PCD).
This comprehensive review from researchers at Shanghai University of Traditional Chinese Medicine examines how macrophage senescence and multiple PCD pathways interact to accelerate atherosclerotic disease. Senescent macrophages are defined by irreversible cell cycle arrest, mitochondrial dysfunction, and the secretion of a pro-inflammatory cocktail known as the senescence-associated secretory phenotype (SASP). SASP signals amplify local inflammation and critically impair efferocytosis — the process by which dead cells are cleared from plaques — leading to necrotic core expansion and plaque instability.
Meanwhile, PCD pathways including apoptosis, necroptosis, pyroptosis, ferroptosis, and autophagy each play context-dependent roles. Dysregulated necroptosis and pyroptosis in particular feed the necrotic core and sustain inflammatory cascades. The review identifies shared molecular regulators — NF-κB, mTOR, and p53 — that govern both senescence and PCD, creating potential nodes for therapeutic intervention.
On the therapeutic front, the authors survey an exciting array of emerging strategies: senolytic agents that selectively clear senescent cells, NLRP3 inflammasome inhibitors that dampen pyroptosis-driven inflammation, ferroptosis suppressors, and autophagy enhancers. Pharmacological agents such as quercetin and melatonin are highlighted as accessible compounds that may modulate these pathways.
Caveats include the largely preclinical nature of the evidence base and the mechanistic complexity of targeting multiple overlapping pathways simultaneously. Translation to human clinical trials remains a key next step.
Key Findings
- Senescent macrophages release SASP signals that destabilize plaques and block clearance of dead cells inside arteries.
- Necroptosis and pyroptosis enlarge necrotic cores in atherosclerotic plaques, accelerating disease progression.
- NF-κB, mTOR, and p53 are shared master regulators of both macrophage senescence and programmed cell death.
- Senolytics, NLRP3 inhibitors, and ferroptosis suppressors show preclinical promise for plaque stabilization.
- Quercetin and melatonin may disrupt the senescence-PCD axis through p38 MAPK inhibition and Nrf2 activation.
Methodology
This is a narrative review article synthesizing published mechanistic and preclinical research on macrophage senescence and programmed cell death in atherosclerosis. The authors map molecular pathway cross-talk and evaluate therapeutic strategies based on existing literature rather than original experimental data. No systematic search protocol or meta-analytic methods are described.
Study Limitations
The summary is based on the abstract only, as the full text is not open access. The evidence base is largely preclinical, limiting direct clinical translation. The review does not appear to follow systematic review methodology, which increases risk of selection bias in the literature synthesized.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: